Illinois Nurse Newlove Stripped of DEA Access Over Expired Credentials
Published Date: 7/8/2025
Notice
Summary
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
DEA Registration Revoked for Nurse Practitioner
The Drug Enforcement Administration revoked Tanya Newlove's DEA Certificate of Registration No. MD3642077, effective August 6, 2025. This means she can no longer legally handle or dispense controlled substances after that date because her Illinois licenses expired on June 30, 2024.
Pending Renewal/Additional Applications Denied
The Order denies any pending applications by Tanya Newlove to renew or modify her DEA registration and any pending application for additional registration in Illinois. The denial accompanies the revocation and is included in the Order effective August 6, 2025.
State License Required to Hold DEA Registration
The decision restates that a practitioner must be authorized under the laws of the State in which they practice to dispense controlled substances in order to obtain or maintain a DEA registration. If a practitioner's state license is suspended, revoked, or expired, DEA may revoke the practitioner’s registration.
Failing to Request Hearing Can Lead to Default Revocation
The Order notes that the registrant was served an Order to Show Cause and did not request a hearing, which resulted in a default. Under 21 CFR 1301.43, a default can be deemed a waiver of the right to a hearing and can support a final order revoking registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-12608 — William Washington, M.D.; Decision and Order
Dr. William Washington lost his medical license in Washington state, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final and immediate. This means Dr. Washington can no longer legally prescribe or manage controlled drugs, effective right now.
Next: 2025-12610 — Mark Agresti, M.D.; Decision and Order
Dr. Mark Agresti from Florida lost his DEA registration because he was convicted of health care fraud and excluded from federal health programs. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can no longer legally prescribe controlled substances, effective immediately, impacting his medical practice and patients.